

Available at NeoGenomics

Last Updated August 26, 2020

Cancer Type	Therapy	Test	Test Cut-Off
Non-Small Cell Lung Carcinoma (NSCLC)	Keytruda® (pembrolizumab)	PD-L1 IHC 22C3 pharmDx	TPS ≥1%
	Opdivo® (nivolumab)	PD-L1 IHC 28-8 pharmDx	≥1% TC
	Tecentriq® (atezolizumab)	Ventana PD-L1 SP142 Assay (IHC)	≥50% TC OR ≥10% IC
Breast (TNBC)	Tecentriq® (atezolizumab)	Ventana PD-L1 SP142 Assay (IHC)	≥1% IC
Cervical	Keytruda® (pembrolizumab)	PD-L1 IHC 22C3 pharmDx	CPS ≥1
Colorectal Cancer	Keytruda® (pembrolizumab)	Mismatch Repair (MMR) IHC or Microsatellite Instability (MSI), <i>LDT OK</i>	MMR-deficient or MSI-high
	Opdivo® (nivolumab)		MMR-deficient or MSI-high
Endometrial	Keytruda® (pembrolizumab)	Mismatch Repair (MMR) IHC or Microsatellite Instability (MSI), <i>LDT OK</i>	not MMR-deficient or not MSI-high
Esophageal (ESCC)	Keytruda® (pembrolizumab)	PD-L1 IHC 22C3 pharmDx*	CPS ≥10
Gastric/GEA	Keytruda® (pembrolizumab)	PD-L1 IHC 22C3 pharmDx	CPS ≥1
Head & Neck (HNSCC)	Keytruda® (pembrolizumab)	PD-L1 IHC 22C3 pharmDx*	CPS ≥1
Melanoma	Tecentriq® (atezolizumab)	FDA-approved BRAF mutation test <i>THxID® BRAF by PCR for Melanoma at NeoGenomics</i>	BRAF V600-mutation positive
Solid Tumors	Keytruda® (pembrolizumab)	Mismatch Repair (MMR) IHC or Microsatellite Instability (MSI), <i>LDT OK</i>	MMR-deficient or MSI-high
	Keytruda® (pembrolizumab)	Tumor Mutation Burden (TMB) <i>LDT at NeoGenomics</i>	TMB-High
Urothelial Carcinoma (UC)	Keytruda® (pembrolizumab)	PD-L1 IHC 22C3 pharmDx*	CPS ≥10
	Tecentriq® (atezolizumab)	Ventana PD-L1 (SP142) Assay (IHC)	≥5% IC

Please refer to full drug prescribing information to verify indications, therapy combinations, and use for your patient's case. There may be additional indications unrelated to testing.

See scoring abbreviations on back



*28-8 and 22C3 pharmDx testing on HNSCC and UC tissues and 22C3 testing on esophageal tissue use controls of non-matched tissue types which is a variation from the kit instructions. NSCLC controls are tissue-matched per kit instructions.

Phone: 866.776.5907
neogenomics.com

Checkpoint Inhibitor Companion Diagnostics (Continued)

Abbreviations

CPS = Combined Positive Score

IC = Percent Positive Tumor-Associated Immune Cells

TC = Positive Tumor Cells

TPS = Tumor Proportion Score

LDT = Lab-Developed Test

Sources

Current drug prescribing information and test kit package inserts.



Phone: 866.776.5907
neogenomics.com

© 2020 NeoGenomics Laboratories, Inc. All Rights Reserved.
All trademarks, logos and service marks are the property of their respective owners.
CORP-MRKT-0003 Rev. 082620